SLC7A6OS

Across TCGA pan-cancer cohorts, SLC7A6OS mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC7A6OS’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC7A6OS mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC7A6OS is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where SLC7A6OS tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC7A6OS mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.523	<.001	12	view →
LUAD	Male	II,III,IV	−0.451	<.001	8	view →
LSCC	Male	All	−0.137	.002	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SLC7A6OS–CCRCC

Open the CCRCC breakdown →